BML Investment Partners Urges ESSA Pharma (EPIX) to Liquidate and Return Cash to Shareholders
Key Summary: On April 15, 2025, Soleus Capital (5.1%) urged ESSA Pharma to wind down operations and return cash to shareholders, citing macro pressures and the stock trading below cash per share following the halted EPI-7386 trials. On April 24, 2025, BML Investment Partners (9.5%) urged the Board to pursue an orderly winddown, liquidation, and capital return, citing shareholders' best interests.
Market Cap: $79 million | ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
On April 15, 2025, Soleus Capital (5.1%) sent a letter to the Board commending ESSA Pharma’s historical execution and transparency but urged a wind-down of operations and return of capital to shareholders, citing macroeconomic pressures and the stock trading below cash per share (~$2.40 vs. $1.60), following the termination of EPI-7386 trials.
On April 24, 2025, BML Investment Partners (9.5%) sent a letter to the Board expressing its belief that an orderly winddown, liquidation, and capital return is in the best interets of the shareholders of the company.
Member discussion